Evidence map›Paper›PMID 33941513›Full record

Trial reportBMJ global health2021

The mortality effects of disregarding the strategy to save doses of measles vaccine: a cluster-randomised trial in Guinea-Bissau.

Stine Byberg, Peter Aaby, Amabelia Rodrigues, Christine Stabell Benn, Ane Baerent Fisker

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01306006 (The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age), which is not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01306006 phase4completednot on this map

The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age

TypeinterventionalSponsorBandim Health ProjectRan2011 to 2017Enrolled3,500ConditionsMortality, VaccinesArmsProviding measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Stine BybergBandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.ORCID 0000-0002-3626-3609
Peter AabyBandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.
Amabelia RodriguesBandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.
Christine Stabell BennBandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.
Ane Baerent FiskerBandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau afisker@health.sdu.dk.ORCID 0000-0002-8521-0992
Statens Serum Institut · DKBandim Health Project · GW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMeasles vaccine (MV) may improve health beyond measles protection. To avoid wastage from multi-dose vials, children in Guinea-Bissau are only measles vaccinated when aged 9-11 months and when six or more children are present. We assessed health impacts of providing MV to all measles-unvaccinated children 9-35 months.

methodsWe cluster-randomised 182 village clusters under demographic surveillance in rural Guinea-Bissau to an 'MV-for-all-policy' arm where we offered MV regardless of age and number of children present at our bi-annual village visits, or a 'Restrictive-MV-policy' arm where we followed national policy. Measles-unvaccinated children aged 9-35 months were eligible for enrolment and followed to 5 years of age. In intention-to-treat analyses, we compared mortality using Cox regression analyses with age as underlying timescale. The primary analysis was for children aged 12-35 months at eligibility assessment. Interactions with several background factors were explored.

resultsBetween 2011 and 2016, we followed 2778 children in the primary analysis. MV coverage by 3 years was 97% among children eligible for enrolment under the MV-for-all-policy, and 48% under the Restrictive-MV-policy. Mortality was 59% lower than anticipated and did not differ by trial arm (MV-for-all-policy: 45/1405: Restrictive-MV-policy: 44/1373; HR: 0.95 (95% CI 0.64 to 1.43)). The effect of MV-for-all changed over time: The HR was 0.53 (95% CI 0.27 to 1.07) during the first 1½ years of enrolment but 1.47 (95% CI 0.87 to 2.50) later (p=0.02, test of interaction). Explorative analyses indicated that the temporal change may be related to interactions with other childhood interventions.

conclusionThe MV-for-all-policy increased MV coverage but had no overall effect on overall mortality. TRIAL REGISTRATION NUMBER: NCT01306006.

Indexed as

MeaslesMeasles VaccineChildGuinea-BissauHumansMeasles Vaccinechild healthepidemiologyimmunisationpublic healthvaccines

Identifiers

PMID33941513
PMCPMC8098964
OpenAlexW3159413993

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.